• 대한핵의학회:학술대회논문집
• /
• 대한핵의학회 2002년도 춘계학술대회 및 총회
• /
• pp.32-36
• /
• 2002

Lymphoma is a group of neoplastic disease of lymphoid tissues, which can be classified into categories of Hodgkin's disease and non-Hodgkin's lymphoma(NHL). Prognosis of lymphoma depends on the extent of disease(staging) especially in Hodgkin's disease, but also depends on the histologic make up in non-Hodgkin's lymphoma. Although non-Hodgkin's lymphoma is a neoplastic transformation of lymphoid cell it is a collection of disease with merphologically and immunologically diverse make up. Consequently the classification of NHL has changed frequently and evolved according to the progress of immunologic and molecular knowledge added to the original morphologic classification. Lymphoma is a disorder sensitive to chemotherapy which often leads to cure of the disease even in advanced stage, while many other patients die from the progression of disease. Therefore, better understanding in newer classification and sensitive imaging technique, such as PET, in lymphoma will likely lead to the improvement of survival rate.

• 대한두경부종양학회지
• /
• 제23권2호
• /
• pp.170-173
• /
• 2007

About 20% of non-Hodgkin' lymphoma occur in the extra-nodal region in the head and neck area and more than half of extra-nodal lymphoma in the head and neck area involves the Waldeyer' ring. Malignant lymphoma arising in the parotid glands are relatively rare, although 90% of all salivary gland lymphomas, appear in parotid gland and are classified as extranodal non Hodgkin' lymphoma. We experienced one rare case of non-Hodgkin' lymphoma in the right parotid gland, with a painless swelling of the cheek region as the chief complaint. We treated with CHOP(cyclophosphamide, $750mg/m^2$ i.v. day1 ; doxorubicin, $50mg/m^2$ i.v. day 1 ; vincristine, $1.4mg/m^2$ i.v. day 1;prednisone, $50mg/m^2$ orally days 1 to 5. repeat every 21 days) and Rituximab combination therapy. We aimed to report here one case of non-Hodgkin' lymphoma in the right parotid gland with review of literature.

• 대한한방내과학회지
• /
• 제37권3호
• /
• pp.453-466
• /
• 2016

Objective: The purpose of this study was to present the clinical practice guideline of Korean medicine for malignant lymphoma.Background: Malignant lymphoma is the tenth most common cancer in Korea. The two main types of lymphoma are Hodgkin’s disease and non-Hodgkin’s lymphoma. Non-Hodgkin’s lymphomas are more common, comprising nearly 95 percent of all lymphomas. In China, the traditional Chinese medicine clinical guidelines for malignant lymphoma were published in 2014. Therefore, there is growing need for a clinical practice guideline in Korea, which has not thus far existed. This clinical practice guideline was created by reviewing the Chinese clinical practice guideline and Korean clinical reports. This study will be helpful in understanding malignant lymphoma and in understanding its treatment in Korean medicine.Conclusion: Further clinical research on malignant lymphoma is needed to develop a more advanced clinical guideline.

• Radiation Oncology Journal
• /
• 제2권1호
• /
• pp.49-58
• /
• 1984

53 patients of previously untreated Stage I&II Non-Hodgkin's Lymphoma in head and neck treated with irradiation at Yonsei Cancer Center from January, 1970 to December, 1978 were retrospectively analysed. 5 year survival rate and 5 year disease free survival rate were $51.5\%\;and\;42\%$. Local control rate by irradiation was $92.4\%$ with mainly $4,000\~6,000$ rads. 21 patients suffered relapses after radiotherapy, 4 cases recurred within irradiated area, 4 cases at contiguous site of irradiation field, and 13 cases recurred at distant area, more commonly below diaphragm. Most cases relapsed within 1 year 6 months after treatment. Optimum irradiation field for head and neck localized lymphoma, prognostic factors ana usefulness of chemotherapy are also discussed.

• 대한두개안면성형외과학회지
• /
• 제11권2호
• /
• pp.99-102
• /
• 2010

Purpose: Primary malignant lymphomas of the salivary glands are uncommon, representing only 1.7% to 3.1% of all salivary neoplasms and 0.6% to 5% of all tumors and tumor-like lesions of the parotid gland. Lymphomas of the parotid glands are usually manifestations of a systemic disease process but primary lymphomas of the parotid glands are rare. Most of these lesions are classified as extranodal non-Hodgkin's lymphoma. We report the clinicopathological features of primary malignant lymphoma of the parotid gland based on an analysis of our cases. Methods: The subject was a 48-year-old male patient with a malignant lymphoma originating in the parotid gland, which had been slowly increasing in size over previous 6 months. The diagnosis was established by MRI and a superficial lobectomy. After diagnosis, the patient was referred to an oncologist for staging and medical treatment. Results: The stage was IIIA. The patient was treated with chemotherapy following surgery with rituximab and CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisolone). The tumor was controlled successfully by chemotherapy. The patient was followed up for 1 year with no relapse. Conclusion: A case of primary non-Hodgkin's lymphoma of the parotid gland was treated with a superficial parotidectomy and chemotherapy. The disease was well controlled after a 1 year follow-up.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권5호
• /
• pp.2051-2054
• /
• 2015

Background: Radiation therapy is a key part of the combined modality treatment for Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), which can achieve locoregional control of disease. The 3D-conformal radiation oncology can be extended-field (EFRT), involved-field (IFRT) and involved node (INRT). New techniques have resulted in a smaller radiation field and lower dose for critical organs such as lung heart and breast. Materials and Methods: In our research, we made a virtual simulation for one patient who was treated in four different radiotherapeutic techniques: mantle field (MFRT), EFRT, IFRT and INRT. After delineatiion we compared dose-volume histograms for each technique. The fusion of CT for planning radiotherapy with the initial PET/CT was made using Softver Xio 4.6 in the Focal program. The dose for all four techniques was 36Gy. Results: Our results support the use of PET/CT in radiation therapy planning. With IFRT and INRT, the burden on the organs at risk is less than with MFRT and EFRT. On the other hand, the dose distribution in the target volume is much better with the latter. Conclusions: The aim of modern radiotherapy of HL and NHL is to reduce the intensity of treatment and therefore PET/CT should be used to reduce and not increase the amount of tissue receiving radiation.

• 대한두경부종양학회지
• /
• 제15권1호
• /
• pp.22-28
• /
• 1999

Purpose: We performed this study retrospectively to evaluate local control, survival, prognostic factors, and failure patterns in patients with non-Hodgkin's lymphoma of Waldeyer's ring. Materials and Methods: From April 1984 to November 1996,41 patients with non-Hodgkin's lymphoma of Waldeyer's ring were treated with combined chemotherapy and radiation therapy. Age was ranged from 19 to 73 years old with a median age of 55 years, and there were 26 male and 15 female patients. Primary site was tonsil in 26 and base of the tongue in 7 and nasopharynx in 8, and stage distribution showed stage I in 12 and stage II in 29 patients. Pathologic classification was done according to Working Formulation. There were 1 with follicular mixed small cleaved and large cell, 8 with diffuse small cleaved cell, 7 with diffuse mixed small and large cell, and 25 cases with diffuse large cell. All patients were treated with combination of chemotherapy and radiation therapy. Chemotherapy regimen consisted of either CHOP-Bleo(cyclophosphamide, adriamycin, vincristine, prednisolone, bleomycin) or COP-BLAM III(cyclophosphamide, vincristine, prednisolone, bleomycin, adriamycin, procarbazine). Radiation dose ranged from 3600cGy to 6620cGy with a median dose of 5040cGy. Follow-up time was ranged from 15 months to 159 months(median 55 months). Results: The complete response was achieved in 98%(40/41) and partial response in 2%(1/41). The complete response rate were the followings: 66.7% for stage I and 51.7% for stage II after chemotherapy, 100% for stage I and 96.6% for stage II after overall treatment respectively. The overall survival rate and disease-tree survival rates at 5 years were 82.6% and 79.5%, respectively. Prognostic factors for overall survival were age(p=0.007), stage(p=0.03), nodal status(p=0.006) and radiation dose(p=0.003). The factors associated with disease-tree survival were stage(p=0.04), nodal status(p=0.004) and radiation dose(p=0.009). The failure patterns were analized in evaluable 35 patients with complete response. Locoregional failure was noted in 2 patients and distant metastasis in 5 patients. Conclusion: Our results suggest that combined modality therapy is the appropriate treatment for stage I-II intermediate grade non-hodgkin's lymphoma of the Waldeyer's ring. However, our material is small and the analysis is retrospective. Randomized prospective studies for combined therapy, radiation therapy alone and chemotherapy alone are needed.

• Radiation Oncology Journal
• /
• 제8권2호
• /
• pp.255-260
• /
• 1990

1985년 4월부터 1989년 9월까지 경북대학교병원 치료방사선과에서 두경부 악성 임파종으로 진단되어 복합화학요법 및 방사선 병용치료를 받은 26명을 대상으로 치료성적을 분석하였다. 완전관해율은 $88{\%}$, 부분관해율은 $12{\%}$였고 관해율에 영향을 미치는 예후인자는 없었다. 3년 생존율 및 3년무병생존율은 각각 $62.4{\%}$및 $65.2{\%}$였다. 생존율이 높았던 군은 편측성 임파절침범(p<0.05), 방사선량 5000 cGy 이상 (p<0.01), 화학요법 6회 이상 (p=0.06)등이었다. 26예 중 8예 (부분관해 3예 포함)에서 재발을 했으며 재발 양상은 국소재발 1예, 원격 전이 1예, 인접조직에 재발 1예, 국소 재발 및 원격전이 2예 등이었다.

• Investigative Magnetic Resonance Imaging
• /
• 제18권2호
• /
• pp.176-181
• /
• 2014

유방의 일차성 비호지킨림프종은 드문 종양으로 유방촬영술과 초음파에서 다양한 영상소견을 보인다. 하지만 자기공명영상소견은 여러개의 증례로만 보고되어 있고, 자기공명분광법과 확산강조영상에 대한 보고는 거의 없다. 저자들은 유방의 일차성 비호지킨림프종을 진단받은 두명의 여자환자의 증례를 기본 자기공명영상에 더하여 자기공명 분광법 및 확산강조 영상소견과 함께 보고하고자 한다. 종양은 유방촬영술과 초음파에서 경계가 좋은 종괴로 나타났으며, 조영증강자기공명영상에서 강한 조영증강을 보였다. 또한 다른 악성종양에서 나타나는 것과 같이 확산강조영상에서는 확산제한을 보이고, 자기공명분광법에서는 콜린값이 증가하는 소견을 보였다.

• Radiation Oncology Journal
• /
• 제9권1호
• /
• pp.103-109
• /
• 1991

I, II기 intermediate grade악성 임파종에서 방사선 치료의 역할을 극인하기 위하여 서울대학교 병원 치료 방사선과에서 치료받은 162예의 방사선 치료 성적을 분석하였다. 초기의 치료 실패 양상 이 확인 가능한 68 예 중 38.2%는 조사야 내에서 61.8%는 조사야 밖에서 치료 실패 또는 재발 하였다. I기에서는 조사야 내 및 외에서 발생한 치료 실패 양상은 국소 조사야 치료시 각각 30.0%와 70.0%였고, 확대 조사야 치료시는 각각 43.8% 와 56.2%였다. II기에서는 각각 16.7% 와 83.3% 및 41.7%와 58.3%였다. 5년 무병 생존율은 전 환자에서 48.1%였고, I기 및 II기에서 각각 56.3%와 40.4%로 병기에 따른 유의한 차이가 있었다. 10cm 이상의 종괴나 전신적 증상은 무병 생존율에 영향을 미치지 못하였다. 방사선 치료 범위가 큰 경우에 5년 무병 생존율이 양호하였고 특히 I기에서는 유의하였다. 재발후에 시행한 전신 화학요법의 효과를 감안한 5년 생존율은 I, II기에서 각각 65.3% 및 52.2%였으며 병기에 따른 유의한 차이는 없었다. 따라서 5년 무병 생존율을 향상시키기 위해서는 원발 병소와 인접한 임파절 부위를 포함하는 화대 조사야로 치료할 필요가 있으며 재발된 경우에는 전신 화학 요법이 유용할 것으로 시사된다.